Cellumed셀루메드
049180 · KOSDAQ · ₩049180 · 셀루메드
₩1,009 ₩0 (0.00%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩140B | ₩129B | ₩96B | ₩122B | ₩100B |
| Cost of sales | ₩134B | ₩120B | ₩90B | ₩108B | ₩86B |
| Gross profit | ₩6.6B | ₩9.5B | ₩5.6B | ₩14B | ₩14B |
| Operating income | −₩5.1B | −₩6.8B | −₩10B | −₩2.7B | ₩4.7B |
| Net income | −₩2.2B | −₩32B | −₩38B | −₩5.4B | ₩8.4B |
| Net income to shareholders | −₩2.2B | −₩32B | −₩37B | −₩5.6B | ₩8.2B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩61B | ₩70B | ₩66B | ₩93B | ₩96B |
| Current assets | ₩45B | ₩52B | ₩50B | ₩66B | ₩73B |
| Cash and equivalents | ₩7B | ₩9.6B | ₩6.2B | ₩10B | ₩21B |
| Total liabilities | ₩53B | ₩61B | ₩43B | ₩38B | ₩47B |
| Current liabilities | ₩51B | ₩58B | ₩39B | ₩34B | ₩43B |
| Borrowings | ₩13B | ₩8.8B | ₩15B | ₩11B | ₩13B |
| Total equity | ₩8.4B | ₩9.1B | ₩23B | ₩55B | ₩49B |
| Shareholders' equity | ₩8.4B | ₩8.8B | ₩22B | ₩54B | ₩48B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩3.9B | −₩419M | −₩5.4B | −₩8.3B | −₩2.7B |
| Capital spending | ₩286M | ₩1.8B | ₩4.2B | ₩1.8B | ₩2.3B |
| Free cash flow | −₩4.1B | −₩2.2B | −₩9.5B | −₩10B | −₩4.9B |
| Dividends paid | — | — | — | — | ₩1.9B |
Consolidated where available. Amounts in won.
Also known as: Cellumed / 셀루메드 / 049180 / KRX:049180
Source: KRX statistical information